<DOC>
	<DOC>NCT00329082</DOC>
	<brief_summary>To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.</brief_summary>
	<brief_title>Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>At least 50 years of age and diagnosed with mild to moderate Alzheimer's disease or healthy volunteers fluent in reading and speaking English AD patients must have a reliable study partner who will be in frequent contact with the patient and comply with protocol requirements AD patients who have received AChEIs or memantine for at least 4 months and on stable therapy for at least 2 months prior to starting study drug Have a history of serious infectious disease affecting the brain, head trauma, cancer, drug or alcohol abuse in the past 5 years Have serious or uncontrolled health problems or laboratory tests Multiple or severe drug allergies Prior participation in an active immunization study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>